BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:4073-8. [PMID: 28008230 DOI: 10.2147/DDDT.S117080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, Islampanah M, Naghsh N, Abbasalizadeh M, Deravi N, Abd Elhakim Y. Iron Chelators in Treatment of Iron Overload. Journal of Toxicology 2022;2022:1-18. [DOI: 10.1155/2022/4911205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kontoghiorghes GJ. Ethics in Medicines: Exposing Unethical Practices and Corruption in All Sectors of Medicines Is Essential for Improving Global Public Health and Saving Patients' Lives. Medicines (Basel) 2021;8:54. [PMID: 34564096 DOI: 10.3390/medicines8090054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kontoghiorghes GJ. Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines (Basel) 2021;8:36. [PMID: 34357152 DOI: 10.3390/medicines8070036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Saleh J, Peyssonnaux C, Singh KK, Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion 2020;54:1-7. [PMID: 32574708 DOI: 10.1016/j.mito.2020.06.008] [Cited by in Crossref: 65] [Cited by in F6Publishing: 124] [Article Influence: 32.5] [Reference Citation Analysis]
5 Vinchi F, Hell S, Platzbecker U. Controversies on the Consequences of Iron Overload and Chelation in MDS. Hemasphere 2020;4:e357. [PMID: 32647792 DOI: 10.1097/HS9.0000000000000357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Macías-Rodríguez RU, Inzaugarat ME, Ruiz-Margáin A, Nelson LJ, Trautwein C, Cubero FJ. Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis-A Novel Form of Non-Apoptotic Cell Death?Int J Mol Sci. 2020;21. [PMID: 32121273 DOI: 10.3390/ijms21051651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]